Contact us Demo our platform

Blog

Urine Metabolites Provide a Comprehensive Picture of the Phenotype

urine metabolites

Urine metabolomics is the analysis of metabolites present in urine samples. It has several advantages over other types of metabolomics, such as blood or tissue analysis, because urine is a non-invasive and easily accessible biofluid that is relatively stable. Additionally, urine contains a wide range of metabolites, including those produced by the kidneys, liver, and gut, providing a more comprehensive picture of an individual’s metabolic status. Urine metabolomics can be used to identify metabolic pathways that are altered in disease, to identify potential biomarkers for early detection and diagnosis, to monitor treatment response, and to identify possible side effects of treatment.

Urine Metabolomics Can Be Leveraged for a Wide Range of Applications

Urine has been used in metabolomics for a wide range of applications. For example, urine metabolomics has been used to identify biomarkers for the early detection and diagnosis of renal diseases, such as acute kidney injury and chronic kidney disease. It has also been used to identify biomarkers for different types of cancer, such as bladder, prostate, and renal cell carcinoma, which can aid in early diagnosis and prognosis. Urine metabolomics has also been pivoted to investigate metabolic disorders, such as diabetes and obesity, and to monitor treatment response. Finally, researchers have used urine metabolomics to understand the metabolic effects of different diets and nutritional interventions.

The Metabolon Global Discovery Panel Analyzes Metabolites in Urine and Other Biofluids

The Metabolon Global Discovery Panel has helped many scientists with the metabolomic analysis of urine samples. The ability to non-invasively test for cancer biomarkers in urine is especially beneficial for screening pediatric patients. Metabolon recently helped identify a novel neuroblastoma biomarker by comprehensively analyzing urine samples from children.1 Metabolon collaborated with another research group and found that urine metabolomics profiling offers a non-invasive means of diagnosing and predicting acute kidney allograft rejection.2

Another research group used the Global Discovery Panel to screen urine samples and found that urine metabolites may provide a non-invasive adjunct diagnostic to cystoscopy for the detection of bladder cancer and recurrent disease management.3 In this case study, Metabolon helped elucidate multiple candidate bladder cancer biomarkers, which may offer predictive value in identifying patients with bladder cancer. Metabolon collaborated with another research group to show that urine can be analyzed as a front-line specimen to screen for inborn errors of metabolism (IEM) through metabolomics.4 The Global Discovery Panel analyzes metabolites in urine and other biofluids. Our technology allows scientists to identify a wide range of metabolites and metabolic pathways, providing a comprehensive understanding of the metabolic status and phenotype of an individual. The Global Discovery Panel’s unrivaled coverage of up to 5,400 semi-quantifiable metabolites can offer the most comprehensive solution to characterize urine samples.

Urine Sample Collection and Handling

Urine sample collection and handling are crucial for ensuring the accuracy and reproducibility of metabolomics results. Fasting is preferred, but not required, prior to urine collection. However, it must be noted if the patient has fasted for 8 to 10 hours prior to specimen collection and received no other nutritional intervention other than water for that time period. The following steps should be followed when collecting and handling urine samples for metabolomics:

  1. Collect 0.25 to 1 mL of urine in a sample vial (polypropylene tube). We recommend the following: Metabolon provided bar-coded collection tubes or 1.5 mL polypropylene tubes may also be used (Eppendorf Cat #022363204 or Fisher Cat #05-402-25).
  2. Immediately place the urine specimen into the freezer (≤-20oC). Store the urine frozen (preferably, at -80°C) until it is ready for shipment.
  3. Frozen specimens should be sent on dry ice to retain -20°C to -80°C temperature during transport.

References

  1. Yokota K, Uchida H, Sakairi M, et al. Identification of novel neuroblastoma biomarkers in urine samples. Sci Rep. Feb 18 2021;11(1):4055. doi:10.1038/s41598-021-83619-w
  2. Suhre K, Schwartz JE, Sharma VK, et al. Urine Metabolite Profiles Predictive of Human Kidney Allograft Status. J Am Soc Nephrol. Feb 2016;27(2):626-36. doi:10.1681/ASN.2015010107
  3. Wittmann BM, Stirdivant SM, Mitchell MW, et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 2014;9(12):e115870. doi:10.1371/journal.pone.0115870
  4. Kennedy AD, Miller MJ, Beebe K, et al. Metabolomic Profiling of Human Urine as a Screen for Multiple Inborn Errors of Metabolism. Genet Test Mol Biomarkers. Sep 2016;20(9):485-95. doi:10.1089/gtmb.2015.0291
Metabolon
Our team is made up of over 45 PhDs, has been published 4,000+ times, and is committed to hard work, excellence, and success through collaboration. With over 15,000 projects, Metabolon has been a trusted partner of researchers for over 25 years.

Topics

Oncology | Population Health | Renal and Urological Disorders

Share this article

Related Blog Posts

See All Blog Posts

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.